← Eichor
Study identifier: NCT07166406 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Condition: Advanced Hepatocellular Carcinoma · Stage III Hepatocellular Carcinoma AJCC v8 · Stage IV Hepatocellular Carcinoma AJCC v8  ·  Sponsor: NRG Oncology

PhasePhase 3
Planned participants226
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase III trial compares the effect of immunotherapy (IO) with stereotactic body radiation therapy (SBRT) to IO alone in treating patients with liver cancer (hepatocellular cancer) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). The usual approach is treatment with IO-based drug combinations, such as atezolizumab and bevacizumab, durvalumab and tremelimumab, or ipilimumab and nivolumab. IO with monoclonal antibodies, such as durvalumab, tremelimumab, atezolizumab, nivolumab and ipilimumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor cells. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Giving IO with SBRT may be more effective than IO alone in helping patients with advanced hepatocellular cancer live longer.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (139)

Alta Bates Summit Medical Center-Herrick CampusBerkeley, California, United StatesRecruiting
Sutter Cancer Centers Radiation Oncology Services-Cameron ParkCameron Park, California, United StatesRecruiting
Palo Alto Medical Foundation-FremontFremont, California, United StatesRecruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine, California, United StatesRecruiting
Palo Alto Medical Foundation-Camino DivisionMountain View, California, United StatesRecruiting
UC Irvine Health/Chao Family Comprehensive Cancer CenterOrange, California, United StatesRecruiting
Palo Alto Medical Foundation Health CarePalo Alto, California, United StatesRecruiting
Sutter Cancer Centers Radiation Oncology Services-RosevilleRoseville, California, United StatesRecruiting
Sutter Roseville Medical CenterRoseville, California, United StatesRecruiting
Sutter Medical Center SacramentoSacramento, California, United StatesRecruiting
University of California Davis Comprehensive Cancer CenterSacramento, California, United StatesRecruiting
California Pacific Medical Center-Pacific CampusSan Francisco, California, United StatesRecruiting

+ 127 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07166406